Healius Limited provides various services and facilities to general practitioners, dentists, physiotherapists, specialists, and other healthcare professionals in Australia. It operates through three segments: Pathology, Medical Centres, and Imaging. The company offers diagnostic imaging services, such as X-ray, ultrasound, computerized tomography, mammography, MRI, positron emission tomography, interventional radiology, and nuclear medicine services; and medical laboratory and pathology services. It also operates medical centers that provide nursing support, pathology, radiology, dental, physiotherapy, and allied health services; and IVF services, eye and skin specialists, skin cancer checks, and consultant specialist doctors. The company operates 70 medical centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in St Leonards, Australia.
Industry, Sector and Symbol
Industry Medical Care
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 2 9432 9400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.81 billion
Profitability
Miscellaneous
Employees12,000
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable
Healius (ASX:HLS) Frequently Asked Questions
What is Healius' stock symbol?
Healius trades on the ASX under the ticker symbol "HLS."
How often does Healius pay dividends? What is the dividend yield for Healius?
Healius declared a Final dividend on Tuesday, August 20th. Shareholders of record on Friday, September 27th will be paid a dividend of 0.034 per share on Friday, September 27th. This represents a yield of 1.13%. The ex-dividend date of this dividend is Thursday, August 29th. View Healius' Dividend History.
How were Healius' earnings last quarter?
Healius Ltd (ASX:HLS) posted its earnings results on Friday, February, 15th. The company reported $0.04 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.06. View Healius' Earnings History.
When is Healius' next earnings date?
Has Healius been receiving favorable news coverage?
Press coverage about HLS stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Healius earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Healius.
Who are some of Healius' key competitors?
Some companies that are related to Healius include Mediclinic International (MDC), NMC Health (NMC), Rhoen Klinikum (RHK), CareTech (CTH), Spire Healthcare Group (SPI), Virtus Health (VRT), Pacific Smiles Group (PSQ), Georgia Healthcare Group (GHG), Assure (IOM), CENTRIC HEALTH (CHH), Sanara MedTech (SMTI), Totally (TLY), Konekt (KKT), Brain Resource (BRC) and Nobilis Health (HLTH).
Who are Healius' key executives?
Healius' management team includes the folowing people:
- Dr. Malcolm W. Parmenter, MD, CEO & Director (Age 64)
- Mr. Malcolm Robert Ashcroft, Chief Financial Officer (Age 45)
- Ms. Maxine Jaquet, Chief Exec. of Health & Co
- Mr. Dean Lewsam, Chief Exec. of Imaging
- Mr. Wesley Lawrence, Chief Exec. of Pathology
What is Healius' stock price today?
One share of HLS stock can currently be purchased for approximately A$2.83.
How big of a company is Healius?
What is Healius' official website?
How can I contact Healius?
The company can be reached via phone at 61 2 9432 9400.
MarketBeat Community Rating for Healius (ASX HLS)
MarketBeat's community ratings are surveys of what our community members think about Healius and other stocks. Vote "Outperform" if you believe HLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
